You are here

  • Home
  • Archive
  • Volume 21, Issue 4
  • In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal
  1. Adrian G McNicholl,
  2. Javier P Gisbert
  1. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
  1. Correspondence to : Dr Javier P Gisbert, Gastroenterology Unit, Hospital de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), c/ Diego de León 62, Madrid 28006, Spain; Javier.p.gisbert{at}gmail.com

http://dx.doi.org/10.1136/ebmed-2016-110458

Statistics from Altmetric.com

    Commentary on: Liou JM, Bair MJ, Chen CC, et al. Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori: a randomized trial. Am J Gastroenterol 2016;111:381–7OpenUrlCrossRefPubMed.

    Context

    Helicobacter pylori infection is the main cause of several gastric diseases including gastritis, peptic ulcer and gastric cancer. Traditional anti-H. pylori treatments fail in up to 20–30% of naive patients requiring intervention. Failed attempts may cause the acquisition of resistance by H. pylori or the selection of resistant/resilient strains, hindering second-line treatments.

    One of the most recommended second-line regimens is triple therapy with levofloxacin (LT); however, its efficacy has never been optimal, with an estimated pooled eradication rate of 79%.1 In order to improve these results, Liou and colleagues performed a randomised trial comparing LT with a levofloxacin containing sequential therapy (LS).

    Methods

    The study was …

    View Full Text

    Footnotes

    • Contributors AGM drafted the manuscript, and JPG critically reviewed it.

    • Competing interests AGM has received funds for a scientific oral presentation in one event promoted by Allergan. JPG has received funds to promote research from – and/or has provided advisory and education activities to – Almirall, Allergan, AstraZeneca, Casen Recordati, Nycomed.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/